Latest Posts
-
Spotting the Next Gullwing: How to Distinguish Breakthrough Biotech from Concept Hype
I’ve always admired the Mercedes 300 SL Gullwing. This wasn’t just a beautiful car – it represented radical engineering leaps. Fuel injection, lightweight frames, bold design choices. At the time, many doubted whether these concepts would succeed. Fast-forward 70 years: it is not just a classic, it is a benchmark of vision, courage, and long-term…
-
CEO Espresso Interview: Rohit Jha
Question: Tell us briefly about Transcelestial and your role as CEO. Answer: Transcelestial is focused on space-based infrastructure — satellites, security, and how we protect data and systems in orbit. I founded the company after working in both government and academia, and we’re trying to bridge that gap: deep tech, but practical applications. Our mission…
-
3 common mistakes in pharma market access negotiations – and how to avoid them
Market access is often the decisive bottleneck: without successful payer negotiations, even the most innovative product will fail commercially. From my experience, three mistakes repeat again and again: These mistakes cost time, credibility, and millions. With structured frameworks and early preparation, they can be avoided. What has been your experience in payer negotiations?